Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.

Zai Lab (NASDAQ:ZLAB) announced Wednesday it would seek marketing approval for its cervical cancer therapy Tivdak (tisotumab ...

January 17, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application ...

Zai Lab (ZLAB) announced that China’s National Medical Products Administration, NMPA, has accepted the New Drug Application, NDA, for KarXT for ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the China National Medical ...

Some of China’s senior doctors are raising concern over the quality of domestic generic medicines that have largely replaced western brand-name drugs at hospitals, amid a rare public backlash against ...

The biotech plans to submit a new drug application to China regulators in the first half of this year, Li said. The asset has also snagged both orphan drug and regenerative medicine advance ...

The Food and Drug Administration (FDA) has accepted a new drug application (NDA) with priority review for ... which was conducted in China, as well as the TRUST-II global study, both of which ...

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...